Literature DB >> 18407849

The cross algorithm for phase-aberration correction in medical ultrasound images formed with two-dimensional arrays.

Yue Li1, Brent Robinson.   

Abstract

Common-midpoint signals in the near-field signal-redundancy (NFSR) algorithm for one-dimensional arrays are acquired using three consecutive transducer elements. An all-row-plus-two-column algorithm has been proposed to implement the one-dimensional NFSR algorithm on two dimensional arrays. The disadvantage of this method is that its ambiguity profile is not linear and a timeconsuming iterative method has to be used to linearize the ambiguity profile. An all-row-plus-two-column-and-a-diagonal algorithm has also been proposed. Its ambiguity profile is linear, but it is very sensitive to noise and cannot be used. In this paper, a novel cross algorithm is proposed to implement the NFSR algorithm on two-dimensional arrays. In this algorithm, common-midpoint signals are acquired using four adjacent transducer elements, which is not available in one-dimensional arrays. Its advantage includes a linear ambiguity profile and a higher measurement signal-to-noise ratio. The performance of the cross algorithm is evaluated theoretically. The region of redundancy is analyzed. The procedure for deriving the phaseaberration profile from peak positions of cross-correlation functions between common-midpoint signals is discussed. This algorithm is tested with a simulated data set acquired with a two-dimensional array, and the result shows that the cross algorithm performs better than the all-row plus-twocolumn NFSR algorithm.

Mesh:

Year:  2008        PMID: 18407849     DOI: 10.1109/TUFFC.2008.684

Source DB:  PubMed          Journal:  IEEE Trans Ultrason Ferroelectr Freq Control        ISSN: 0885-3010            Impact factor:   2.725


  1 in total

1.  Aberration compensation of an ultrasound imaging instrument with a reduced number of channels.

Authors:  Wei Jiang; Jeffrey P Astheimer; Robert C Waag
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2012-10       Impact factor: 2.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.